<!DOCTYPE html>
<html lang="en" style="margin: 0; border: 0; padding: 0">
  <head style="margin: 0; border: 0; padding: 0">
    <meta charset="UTF-8" style="margin: 0; border: 0; padding: 0" />
    <meta
      http-equiv="X-UA-Compatible"
      content="IE=edge"
      style="margin: 0; border: 0; padding: 0"
    />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1.0"
      style="margin: 0; border: 0; padding: 0"
    />
    <!-- <link rel="stylesheet" href="style.css" /> -->
    <title style="margin: 0; border: 0; padding: 0">
      Sanofi Rep Triggered Email - H2H Study
    </title>
    <!-- Internal CSS -->

    <!-- End of Internal CSS-->
  </head>
  <body
    style="
      margin: 0 auto;
      border: 0;
      padding: 2%;
      font-family: 'Open Sans', sans-serif;
      background-color: #fff;
      font-size: 15px;
      max-width: 600px;
    "
  >
    <!-- container wrapper-->
    <div
      id="wrapper"
      style="
        margin: 0;
        border: 1px solid #707070;
        padding: 0;
        background: #ffffff;
        color: #58595b;
      "
    >
      <!-- header email marketing  -->
      <header style="margin: 0; border: 0; padding: 0; width: 98%">
        <div
          id="logo"
          style="
            margin: 0;
            border: 0;
            padding: 2% 4%;
            float: left;
            color: #fff;
            font-size: 10.5px;
            font-weight: 600;
          "
        >
          Please see Important Safety Information below and click
          <u style="margin: 0; border: 0; padding: 0">
            <a
              href="http://products.sanofi.us/Kevzara/Kevzara.pdf"
              target="_blank"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: inherit;
                text-decoration: none;
              "
              >here
            </a>
          </u>
          for full Prescribing Information,
          <br style="margin: 0; border: 0; padding: 0" />
          Including Boxed WARNING.
        </div>
      </header>
      <!-- end of header email marketing  -->

      <!-- banner area image-->
      <div
        class="banner"
        style="margin: 0; border: 0; padding: 0; background-color: #333333"
      >
        <img
          src="https://res.cloudinary.com/lenilunderman/image/upload/v1621297761/axon/heading-image_cmrheu.jpg"
          alt="When it's Time for a Change, Target IL-6R with KEVZARA"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            max-width: 100%;
            object-position: center;
            object-fit: fill;
          "
        />
      </div>
      <!-- end banner area image-->

      <!-- first block content -->
      <div
        class="content-grid"
        style="margin: 2% 0%; border: 0; padding: 0px 4%; width: 90%"
      >
        <div class="first-intro" style="margin: 0; border: 0; padding: 0">
          <span
            id="span-1"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              width: 65%;
              display: inline-block;
            "
          >
            <p style="margin: 0; border: 0; padding: 0">
              [Dear Dr] {{accLname}},
            </p>
            <br style="margin: 0; border: 0; padding: 0" />
            [Thank you for speaking with me. As a follow-up to our discussion, I
            wanted to provide you with a resource as well as with some
            information about the MONARCH superiority study that features
            KEVZARA head-to-head data as a monotherapy vs adalimumab.]
          </span>
          <img
            src="https://res.cloudinary.com/lenilunderman/image/upload/v1621297765/axon/KEVZARA_MasterLogo_mcsnum.png"
            alt="KEVZARA (sarilumab) logo"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              max-width: 100%;
              object-position: center;
              object-fit: fill;
              width: 30%;
              display: block;
              float: right;
            "
          />
        </div>
      </div>
      <!-- end first block content -->

      <!-- beginning of content grid column c-->
      <div class="grid-clumnC" style="margin: 0; border: 0; padding: 0px 4%">
        <div
          class="featured-box"
          style="
            margin: 0;
            border: 1px solid #093c61;
            padding: 2%;
            background-color: #163962;
            color: #fff;
          "
        >
          <h1
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              font-style: bold;
            "
          >
            FEATURED BELOW:
          </h1>
          <p style="margin: 0; border: 0; padding: 0">
            Disease Activity Data Comparing KEVZARA Monotherapy with Adalimumab
          </p>
        </div>
        <div class="columnC-info" style="margin: 0; border: 0; padding: 2% 0%">
          <p
            class="blue-title"
            style="
              margin: 0;
              border: 0;
              padding: 2% 0%;
              color: #163962;
              font-weight: bold;
            "
          >
            PIVOTAL TRIAL AND MONARCH STUDY DESIGNS AND DATA
          </p>
          <p style="margin: 0; border: 0; padding: 0">
            <span
              class="blue-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #163962;
                font-weight: bold;
              "
            >
              MOBILITY STUDY DESIGN:
            </span>
            A 52-week, randomized, double-blind, placebo-controlled, multicenter
            study (N=1197) assessing the efficacy and safety of KEVZARA 200 mg +
            MTX and 150 mg + MTX in patients with moderate to severe active RA
            (duration of ≥3 months) who had been on MTX 10 mg to 25 mg/week ≥6
            weeks. Primary endpoints were reduction of signs and symptoms
            (ACR20) at 24 weeks, change in van der Heijde mTSS at 52 weeks, and
            change from baseline in HAQ-DI at 16 weeks. After week 16 in
            MOBILITY, patients with an inadequate response could have been
            treated with open-label KEVZARA 200 mg every 2 weeks.
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
              >1</sup
            >
          </p>
          <p style="margin: 0; border: 0; padding: 0">
            <br style="margin: 0; border: 0; padding: 0" />
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
            >
              CO-PRIMARY ENDPOINT DATA (MTX-IR)
              <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
                >1-3</sup
              >
            </span>
            <br style="margin: 0; border: 0; padding: 0" />
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
            >
              ACR20 response at week 24: </span
            >Patients achieved 66%* with KEVZARA 200 mg + MTX compared to 33%
            with placebo + MTX.
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p style="margin: 0; border: 0; padding: 0">
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
              >ΔHAQ-DI at week 16:</span
            >
            -0.58* with KEVZARA 200 mg + MTX compared to -0.30 with placebo +
            MTX.
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p style="margin: 0; border: 0; padding: 0">
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
            >
              ΔmTSS from baseline at week 52:
            </span>
            0.25 with KEVZARA 200 mg vs 2.78 with placebo*. KEVZARA 200 mg + MTX
            provided an absolute difference of -2.52 units (CI: -3.38, -1.66) in
            mean ΔmTSS relative to placebo + MTX.
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p style="margin: 0; border: 0; padding: 0">
            <span
              class="orange-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #f04f23;
                font-weight: bold;
              "
            >
              TARGET STUDY DESIGN:
            </span>
            A 24-week, randomized, double-blind, parallel group,
            placebo-controlled, multicenter study (N=546) assessing the efficacy
            and safety of KEVZARA 200 mg and 150 mg added to background
            conventional DMARD(s) in adult patients with moderate to severe
            active RA (≥6 months duration) with inadequate response and/or
            intolerance to 1 or more TNF antagonists, when administered with
            background conventional DMARD(s). Primary endpoints were reduction
            of signs and symptoms (ACR20) at 24 weeks and change from baseline
            in HAQ-DI at 12 weeks. After week 12 in TARGET, patients with an
            inadequate response could have been treated with open-label KEVZARA
            200 mg every 2 weeks.
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">
              4</sup
            >
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p style="margin: 0; border: 0; padding: 0">
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
            >
              CO-PRIMARY ENDPOINT DATA (TNF-IR)
              <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">
                2-4</sup
              >
            </span>
            <br style="margin: 0; border: 0; padding: 0" />
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
            >
              ACR20 response at week 24:
            </span>
            Patients achieved 61%* with KEVZARA 200 mg + DMARD(s) compared to
            34% with placebo + DMARD(s).
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p style="margin: 0; border: 0; padding: 0">
            <span
              class="gray-title"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: #58595b;
                font-weight: bold;
              "
              >ΔHAQ-DI at week 12:
            </span>
            -0.49
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
              >†</sup
            >
            with KEVZARA 200 mg + DMARD(s) compared to -0.29 with placebo +
            DMARD(s).
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <span
            class="ital-info"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 12px;
              font-style: italic;
            "
          >
            *P < 0.0001;
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
              >†</sup
            >
            P < 0.01.</span
          >
        </div>
      </div>
      <div
        class="safety-information"
        style="margin: 2% 0%; border: 0; padding: 0px 4%"
      >
        <h1
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 20px;
            color: #093c61;
          "
        >
          IMPORTANT SAFETY INFORMATION
        </h1>
        <div
          class="warning-box"
          style="
            margin: 2% 0%;
            border: 2px solid #093c61;
            padding: 2%;
            color: #093c61;
            font-weight: bold;
          "
        >
          <h1
            class="warning-title"
            style="
              margin: 0;
              border: 0;
              padding: 2% 0px;
              font-size: 17px;
              color: #093c61;
              text-align: center;
            "
          >
            WARNING: RISK OF SERIOUS INFECTIONS
          </h1>
          <p
            style="
              margin: 0;
              border: 0;
              padding: 0px 2%;
              font-size: 15px;
              color: #093c61;
              text-align: left;
            "
          >
            Patients treated with KEVZARA are at increased risk for developing
            serious infections that may lead to hospitalization or death.
            Opportunistic infections have also been reported in patients
            receiving KEVZARA. Most patients who developed infections were
            taking concomitant immunosuppressants such as methotrexate or
            corticosteroids.
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p
            style="
              margin: 0;
              border: 0;
              padding: 0px 2%;
              font-size: 15px;
              color: #093c61;
              text-align: left;
            "
          >
            Avoid use of KEVZARA in patients with an active infection.
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <p
            style="
              margin: 0;
              border: 0;
              padding: 0px 2%;
              font-size: 15px;
              color: #093c61;
              text-align: left;
            "
          >
            Reported infections include:
          </p>
          <br style="margin: 0; border: 0; padding: 0" />
          <ul
            class="list-warning"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              margin-left: 6%;
              margin-right: 4%;
            "
          >
            <li style="margin: 0; border: 0; padding: 2px 0px; padding-top: 2%">
              Active tuberculosis, which may present with pulmonary or 
              extrapulmonary disease. Patients should be tested for latent 
              tuberculosis before KEVZARA use and during therapy. Treatment  for
              latent infection should be initiated prior to KEVZARA use.
            </li>
            <li style="margin: 0; border: 0; padding: 2px 0px; padding-top: 2%">
              Invasive fungal infections, such as candidiasis, and pneumocystis.
               Patients with invasive fungal infections may present with 
              disseminated, rather than localized, disease.
            </li>
            <li style="margin: 0; border: 0; padding: 2px 0px; padding-top: 2%">
              Bacterial, viral and other infections due to opportunistic
              pathogens.
            </li>
          </ul>
          <p
            style="
              margin: 0;
              border: 0;
              padding: 0px 2%;
              font-size: 15px;
              color: #093c61;
              text-align: left;
            "
          >
            <br style="margin: 0; border: 0; padding: 0" />Closely monitor
            patients for signs and symptoms of infection during treatment with
            KEVZARA. If a serious infection develops, interrupt KEVZARA until
            the infection is controlled.
          </p>
          <p
            style="
              margin: 0;
              border: 0;
              padding: 0px 2%;
              font-size: 15px;
              color: #093c61;
              text-align: left;
            "
          >
            <br style="margin: 0; border: 0; padding: 0" />Consider the risks
            and benefits of treatment with KEVZARA prior to initiating therapy
            in patients with chronic or recurrent infection.
          </p>
        </div>
        <div class="common-adverse" style="margin: 0; border: 0; padding: 0">
          <h1
            style="
              margin: 0;
              border: 0;
              padding: 1% 4%;
              font-size: 17px;
              color: #093c61;
              text-align: center;
            "
          >
            Common adverse reactions in pre-rescue,
            <br style="margin: 0; border: 0; padding: 0" />placebo-controlled
            trials
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
              >2‡</sup
            >
          </h1>
          <img
            src="https://res.cloudinary.com/lenilunderman/image/upload/v1621297759/axon/Common_Adverse_Reactions_Table-01_2x_stvmcx.jpg"
            alt="Common adverse reactions in pre-rescue placebo-controlled
          trials"
            style="
              margin: 2% 0px;
              border: 0;
              padding: 0;
              max-width: 100%;
              object-position: center;
              object-fit: fill;
              width: 560px;
              height: 436px;
            "
          />
          <p
            style="
              margin: 0;
              border: 0;
              padding: 0px 1%;
              color: #000000b0;
              font-size: 12px;
            "
          >
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
              >‡</sup
            >Adverse reactions occurring in ≥2% of patients administered KEVZARA
            200 mg or KEVZARA 150 mg + DMARD(s) and greater than observed in
            patients on placebo + DMARD(s).
          </p>
          <ul
            class="list-reactions"
            style="
              margin: 0;
              border: 0;
              padding: 2%;
              font-size: 15px;
              padding-left: 2%;
            "
          >
            <li
              style="
                margin: 0;
                border: 0;
                padding: 2px 0px;
                font-size: 15px;
                margin-top: 2%;
                margin-left: 2%;
              "
            >
              Medically relevant AE occurring at an incidence of less than 2% in
              patients with RA treated with KEVZARA in controlled studies was
              oral herpes
              <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
                >2</sup
              >
            </li>
            <li
              style="
                margin: 0;
                border: 0;
                padding: 2px 0px;
                font-size: 15px;
                margin-top: 2%;
                margin-left: 2%;
              "
            >
              Decrease in ANC was not associated with higher incidence of
              infections, including serious infections
              <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
                >2</sup
              >
            </li>
            <li
              style="
                margin: 0;
                border: 0;
                padding: 2px 0px;
                font-size: 15px;
                margin-top: 2%;
                margin-left: 2%;
              "
            >
              In the long-term safety population, the overall rates of serious
              infections, GI perforations, neutrophil counts, platelet counts,
              and lipid parameters were consistent with what was observed in the
              placebo-controlled trials
              <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
                >2</sup
              >
            </li>
          </ul>
        </div>
      </div>
      <div
        class="grid-clumnC-study"
        style="margin: 0; border: 0; padding: 4%; text-align: left"
      >
        <p style="margin: 0; border: 0; padding: 0">
          <span
            class="light-blue-title"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              color: #009ca7;
              font-weight: bold;
            "
          >
            MONARCH STUDY DESIGN:
          </span>
          A 24-week, randomized, double-blind, double-dummy, phase 3 superiority
          study to evaluate the efficacy and safety of KEVZARA 200 mg q2w
          monotherapy (n=184) vs adalimumab 40 mg q2w monotherapy (n=185) in
          patients who should not continue treatment with MTX due to intolerance
          or inadequate response.
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >‡§||</sup
          >
          The primary endpoint was ΔDAS28-ESR; secondary endpoints included
          ΔDAS28-ESR <2.6, ACR20/50/70, ΔDAS28-CRP, ΔHAQ-DI.
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">5</sup>
        </p>

        <h1 style="margin: 0; border: 0; padding: 0">
          <span
            class="light-blue-title"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              color: #009ca7;
              font-weight: bold;
            "
          >
            MONARCH ADDITIONAL STUDY CONTEXT:
          </span>
        </h1>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            MONARCH data are not included in the KEVZARA full Prescribing
            Information
          </li>
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            DAS28-ESR and FACIT-Fatigue were endpoints in MONARCH; however,
            there are no DAS28-ESR or FACIT-Fatigue data in the KEVZARA USPI
          </li>
        </ul>

        <h1 style="margin: 0; border: 0; padding: 0">
          <span
            class="light-blue-title"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              color: #009ca7;
              font-weight: bold;
            "
          >
            USE OF ADALIMUMAB
          </span>
        </h1>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            Adalimumab and KEVZARA have different indications and can be used
            differently in clinical practice
          </li>
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            Dose escalation from adalimumab 40 mg q2w to 40 mg qw was permitted
            after week 16 in patients who had not achieved at least 20%
            improvement in TJC and SJC. By week 24, dosing for 8.6% of patients
            on adalimumab was adjusted
          </li>
        </ul>

        <h1 style="margin: 0; border: 0; padding: 0">
          <span
            class="light-blue-title"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              color: #009ca7;
              font-weight: bold;
            "
          >
            STUDY LIMITATIONS (MONARCH)
          </span>
        </h1>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            KEVZARA and adalimumab can be used as monotherapy or in combination
            with nonbiologic DMARD(s). In MONARCH, both agents were only used as
            monotherapy
          </li>
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            The efficacy of KEVZARA monotherapy has not been compared to that of
            KEVZARA + MTX or adalimumab + MTX
          </li>
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            MONARCH did not evaluate radiographic outcomes in either treatment
            group
          </li>
        </ul>

        <br style="margin: 0; border: 0; padding: 0" />
        <h1
          class="kevzara-title-info"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            color: #009ca7;
            font-size: 17px;
            line-height: 19px;
            font-weight: bold;
          "
        >
          KEVZARA monotherapy was superior to adalimumab monotherapy in meeting
          primary endpoint of mean change from baseline to week 24 in DAS28-ESR.
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">5</sup>
        </h1>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          <span
            class="bold-text"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              font-weight: bold;
              color: #000000b0;
            "
            >49% greater improvement in DAS28-ESR than adalimumab at week 24
            (primary endpoint) <br style="margin: 0; border: 0; padding: 0" />
          </span>
        </p>

        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            Change from baseline DAS28-ESR at 24 weeks: -3.28
            <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
              >¶ </sup
            >with KEVZARA 200 mg q2w monotherapy compared to -2.20 with
            adalimumab 40 mg q2w monotherapy
          </li>
        </ul>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          <span
            class="bold-text"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              font-size: 15px;
              font-weight: bold;
              color: #000000b0;
            "
            >Given the limitations and context described above, caution should
            be used in interpreting these data.
          </span>
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="small-paragraph"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 12px;
            line-height: 19px;
            text-align: left;
          "
        >
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">‡</sup
          >Efficacy analyses were conducted in the ITT population, which
          included all randomized patients, including those who increased the
          dose frequency of adalimumab or matching placebo. Data collected after
          permanent treatment discontinuation period were excluded;
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">§</sup>
          After week 16, dose escalation to adalimumab qw was permitted for
          patients who did not achieve ≥20% improvement in TJC and SJC;
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >||</sup
          >
          The recommended dose of adalimumab SC is 40 mg q2w. Some patients not
          taking concomitant MTX may derive additional benefit from increasing
          the SC dosing frequency to 40 mg qw; see adalimumab full Prescribing
          Information.
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >5,6</sup
          >
        </p>
        <h1
          class="kevzara-profile-title"
          style="
            margin: 0;
            border: 0;
            padding: 4%;
            text-align: center;
            font-size: 17px;
            color: #009ca7;
            line-height: 19px;
          "
        >
          KEVZARA SAFETY PROFILE AS A MONOTHERAPY
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >3,5</sup
          >
        </h1>
        <img
          src="https://res.cloudinary.com/lenilunderman/image/upload/v1621297778/axon/Monarch_Safety_Table-0B_2x_dmmyvm.jpg"
          alt="kevzara safety profile as monotherapy"
          width="560"
          height="371.49"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            max-width: 100%;
            object-position: center;
            object-fit: fill;
          "
        />
        <br style="margin: 0; border: 0; padding: 0" />
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="small-paragraph"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 12px;
            line-height: 19px;
            text-align: left;
          "
        >
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">#</sup
          >One patient was randomized, but not treated, in the adalimumab group
          and was not included in the safety population; **Patient years per
          group are as follows: 80.5 (adalimumab 40 mg) and 80.1 (KEVZARA 200
          mg);
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >††</sup
          >
          In the randomized trial, 1 patient in the KEVZARA group died of acute
          cardiac failure secondary to aortic dissection and papillary muscle
          rupture on day 36;
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >‡‡</sup
          >
          In the randomized trial, 1 patient receiving KEVZARA was diagnosed
          with infective bursitis and another patient was diagnosed with
          mastitis, and 1 patient receiving adalimumab was diagnosed with
          bacterial arthritis and another patient was diagnosed with a
          respiratory tract infection;
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >§§</sup
          >
          Protocol defined as ≥2 doses within 11 calendar days or within 6 days
          for adalimumab treated patients who switched to weekly dosing;
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px"
            >||||</sup
          >
          Dyslipidemia was defined by standardized MedDRA query.
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">
            5</sup
          >
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="strong-text"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 12px;
            font-weight: bold;
            color: #000000b0;
            text-align: left;
            line-height: 19px;
          "
        >
          The safety profiles of KEVZARA and adalimumab were generally
          comparable, except for neutropenia and injection site erythema for
          KEVZARA and headache and RA for adalimumab.
          <sup style="margin: 0; border: 0; padding: 0; font-size: 11px">5</sup>
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="small-paragraph"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 12px;
            line-height: 19px;
            text-align: left;
          "
        >
          IL-6=interleukin-6; MTX=methotrexate; ACR20=American College of
          Rheumatology 20% improvement criteria; mTSS=mean total Sharp score;
          HAQ-DI=Health Assessment Questionnaire Disability Index; TNF=tumor
          necrosis factor; DAS28-ESR=disease activity score (28 joints) using
          erythrocyte sedimentation rate; DAS28-CRP=disease activity score (28
          joints) using C-reactive protein; FACIT-Fatigue=Functional Assessment
          of Chronic Illness Therapy-Fatigue; USPI=United States Prescribing
          Information; q2w=once every 2 weeks; ALT=alanine aminotransferase;
          ANC=absolute neutrophil count; GI=gastrointestinal; qw=every week;
          TJC=tender joint count; SJC=swollen joint count; PY=patient years;
          TEAE=treatment emergent adverse events.
        </p>
      </div>
      <div
        class="grid-important-safety-information"
        style="margin: 0; border: 0; padding: 0% 3%"
      >
        <h1
          style="
            margin: 0;
            border: 0;
            padding: 2% 0%;
            font-size: 20px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          IMPORTANT SAFETY INFORMATION (cont’d)
        </h1>
        <h2
          style="
            margin: 6px 0px;
            border: 0;
            padding: 2% 0%;
            font-size: 17px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          CONTRAINDICATION
        </h2>
        <p
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 15px;
            color: #58595b;
          "
        >
          Do not use KEVZARA in patients with known hypersensitivity to
          sarilumab or any of the inactive ingredients.
        </p>
        <h2
          style="
            margin: 6px 0px;
            border: 0;
            padding: 2% 0%;
            font-size: 17px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          WARNINGS AND PRECAUTIONS
        </h2>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Infections.</em
              ></strong
            >
            Serious and sometimes fatal infections due to bacterial,
            mycobacterial, invasive fungal, viral, or other opportunistic
            pathogens have been reported in patients receiving immunosuppressive
            agents for rheumatoid arthritis (RA). The most frequently observed
            serious infections with KEVZARA included pneumonia and cellulitis.
            Among opportunistic infections, TB, candidiasis, and pneumocystis
            were reported with KEVZARA.
            <ul class="sub-list" style="margin: 0% 2%; border: 0; padding: 2%">
              <li
                class="sub-list-item"
                style="
                  margin: 2% 0px;
                  border: 0;
                  padding: 2px 0px;
                  color: #000000b0;
                  font-size: 14px;
                  line-height: 19px;
                  list-style-type: ' - ';
                "
              >
                Hold treatment with KEVZARA if a patient develops a serious
                infection or an opportunistic infection.
              </li>
              <li
                class="sub-list-item"
                style="
                  margin: 2% 0px;
                  border: 0;
                  padding: 2px 0px;
                  color: #000000b0;
                  font-size: 14px;
                  line-height: 19px;
                  list-style-type: ' - ';
                "
              >
                Patients with latent TB should be treated with standard
                antimycobacterial therapy before initiating KEVZARA. Consider
                anti‐TB therapy prior to initiation of KEVZARA in patients with
                a past history of latent or active TB in whom an adequate course
                of treatment cannot be confirmed, and for patients with a
                negative test for latent TB but having risk factors for TB
                infection.
              </li>
              <li
                class="sub-list-item"
                style="
                  margin: 2% 0px;
                  border: 0;
                  padding: 2px 0px;
                  color: #000000b0;
                  font-size: 14px;
                  line-height: 19px;
                  list-style-type: ' - ';
                "
              >
                Consider the risks and benefits of treatment prior to initiating
                KEVZARA in patients who have: chronic or recurrent infection, a
                history of serious or opportunistic infections, underlying
                conditions in addition to RA that may predispose them to
                infection, been exposed to TB, or lived in or traveled to areas
                of endemic TB or endemic mycoses.
              </li>
              <li
                class="sub-list-item"
                style="
                  margin: 2% 0px;
                  border: 0;
                  padding: 2px 0px;
                  color: #000000b0;
                  font-size: 14px;
                  line-height: 19px;
                  list-style-type: ' - ';
                "
              >
                Viral reactivation has been reported with immunosuppressive
                biologic therapies. Cases of herpes zoster were observed in
                clinical studies with KEVZARA.
              </li>
            </ul>
          </li>
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Laboratory Abnormalities.</em
              ></strong
            >
            Treatment with KEVZARA was associated with decreases in absolute
            neutrophil counts (including neutropenia), and platelet counts; and
            increases in transaminase levels and lipid parameters (LDL, HDL
            cholesterol, and/or triglycerides). Increased frequency and
            magnitude of these elevations were observed when potentially
            hepatotoxic drugs (e.g., MTX) were used in combination with KEVZARA.
            Assess neutrophil count, platelet count, and ALT/AST levels prior to
            initiation with KEVZARA. Monitor these parameters 4 to 8 weeks after
            start of therapy and every 3 months thereafter. Assess lipid
            parameters 4 to 8 weeks after start of therapy, then at 6 month
            intervals.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Gastrointestinal Perforation.</em
              ></strong
            >
            GI perforation risk may be increased with concurrent diverticulitis
            or concomitant use of NSAIDs or corticosteroids. Gastrointestinal
            perforations have been reported in clinical studies, primarily as
            complications of diverticulitis. Promptly evaluate patients
            presenting with new onset abdominal symptoms.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Immunosuppression.</em
              ></strong
            >
            Treatment with immunosuppressants may result in an increased risk of
            malignancies. The impact of treatment with KEVZARA on the
            development of malignancies is not known but malignancies have been
            reported in clinical studies.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Hypersensitivity Reactions.</em
              ></strong
            >
            Hypersensitivity reactions have been reported in association with
            KEVZARA. Hypersensitivity reactions that required treatment
            discontinuation were reported in 0.3% of patients in controlled RA
            trials. Injection site rash, rash, and urticaria were the most
            frequent hypersensitivity reactions. Advise patients to seek
            immediate medical attention if they experience any symptoms of a
            hypersensitivity reaction. If anaphylaxis or other hypersensitivity
            reaction occurs, stop administration of KEVZARA immediately. Do not
            administer KEVZARA to patients with known hypersensitivity to
            sarilumab.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Active Hepatic Disease and Hepatic Impairment.</em
              >
              Treatment with KEVZARA is not recommended in patients with active
              hepatic disease or hepatic impairment, as treatment with KEVZARA
              was associated with transaminase elevations.
            </strong>
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            <strong style="margin: 0; border: 0; padding: 0"
              ><em style="margin: 0; border: 0; padding: 0"
                >Live Vaccines.</em
              ></strong
            >
            Avoid concurrent use of live vaccines during treatment with KEVZARA
            due to potentially increased risk of infections. No data are
            available on the secondary transmission of infection from persons
            receiving live vaccines to patients receiving KEVZARA.
          </li>
        </ul>
        <h2
          style="
            margin: 6px 0px;
            border: 0;
            padding: 2% 0%;
            font-size: 17px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          ADVERSE REACTIONS
        </h2>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            The most common serious adverse reactions were infections. The most
            frequently observed serious infections included pneumonia and
            cellulitis. The most common adverse reactions (occurred in at least
            3% of patients treated with KEVZARA + DMARDs) are neutropenia,
            increased ALT, injection site erythema, upper respiratory
            infections, and urinary tract infections.
          </li>
        </ul>
        <h2
          style="
            margin: 6px 0px;
            border: 0;
            padding: 2% 0%;
            font-size: 17px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          DRUG INTERACTIONS
        </h2>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            Exercise caution when KEVZARA is co‐administered with CYP substrates
            with a narrow therapeutic index (e.g. warfarin or theophylline), or
            with CYP3A4 substrates (e.g. oral contraceptives or statins) as
            there may be a reduction in exposure which may reduce the activity
            of the CYP3A4 substrate.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            Elevated interleukin‐6 (IL‐6) concentration may down‐regulate CYP
            activity such as in patients with RA and hence increase drug levels
            compared to subjects without RA. Blockade of IL‐6 signaling by
            IL‐6Rα antagonists such as KEVZARA might reverse the inhibitory
            effect of IL‐6 and restore CYP activity, leading to altered drug
            concentrations.
          </li>
        </ul>
        <h2
          style="
            margin: 6px 0px;
            border: 0;
            padding: 2% 0%;
            font-size: 17px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          USE IN SPECIFIC POPULATIONS
        </h2>
        <ul
          class="list-content"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            margin-left: 4%;
            margin-right: 4%;
            word-spacing: 0.5px;
          "
        >
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            KEVZARA should be used in pregnancy only if the potential benefit
            justifies the potential risk to the fetus. Because monoclonal
            antibodies could be excreted in small amounts in human milk, the
            benefits of breastfeeding and the potential adverse effects on the
            breastfed child should be considered along with the mother’s
            clinical need for KEVZARA.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            There is a pregnancy exposure registry that monitors pregnancy
            outcomes in women exposed to KEVZARA during pregnancy. Physicians
            are encouraged to register patients and pregnant women are
            encouraged to register themselves by calling 1‐877‐311‐8972.
          </li>
          <br style="margin: 0; border: 0; padding: 0" />
          <li
            style="
              margin: 0;
              border: 0;
              padding: 2px 0px;
              color: #000000b0;
              font-size: 14px;
              line-height: 19px;
            "
          >
            Use caution when treating the elderly.
          </li>
        </ul>
        <h2
          style="
            margin: 6px 0px;
            border: 0;
            padding: 2% 0%;
            font-size: 17px;
            color: #163962;
            line-height: 19px;
            font-weight: bold;
          "
        >
          INDICATION
        </h2>
        <p
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 15px;
            color: #58595b;
          "
        >
          KEVZARA is indicated for treatment of adult patients with moderately
          to severely active rheumatoid arthritis (RA) who have had an
          inadequate response or intolerance to one or more disease‐modifying
          antirheumatic drugs (DMARDs).
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="patient-advise"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 16px;
            color: #58595b;
            font-weight: bold;
          "
        >
          Advise patients to read the FDA‐approved patient labeling (Medication
          Guide and Instructions for Use).
        </p>
      </div>
      <table
        style="
          margin: 0;
          border: 0;
          padding: 4%;
          color: #000000b0;
          font-size: 15px;
          line-height: 19px;
        "
      >
        <tbody style="margin: 0; border: 0; padding: 0">
          <tr style="margin: 0; border: 0; padding: 0">
            <td style="margin: 0; border: 0; padding: 0">
              <img
                src="https://res.cloudinary.com/lenilunderman/image/upload/v1621297763/axon/HH1077218_SSAU_Clinical_Data_LB_NewCampaign_DIGITAL_L09_Page_1_2x_d90fpx.jpg"
                alt="Thumbnail image"
                width="100"
                height="129.41"
                style="
                  margin: 0;
                  border: 0;
                  padding: 0;
                  max-width: 100%;
                  object-position: center;
                  object-fit: fill;
                "
              />
            </td>
            <td style="margin: 0; border: 0; padding-left: 10px">
              I have included a KEVZARA resource you might find useful.
            </td>
          </tr>
        </tbody>
      </table>
      <!-- end of content grid column c-->
      <!-- end of wrapper -->
      <!-- beginning of content grid column d-->
      <div
        class="learn-more-kevzara"
        style="margin: 0% 3%; border: 0; padding: 0"
      >
        <h1
          style="
            margin: 0;
            border: 0;
            padding: 0;
            font-size: 16px;
            font-weight: 600;
            text-align: center;
            color: #093c61;
            margin-bottom: 10px;
          "
        >
          <a
            href="http://www.kevzarahcp.com/"
            target="_blank"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              color: inherit;
              text-decoration: none;
            "
          >
            <span style="margin: 0; border: 2px solid #093c61; padding: 2%">
              Learn more about KEVZARA</span
            >
          </a>
        </h1>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          Please feel free to contact me for more information or to set up an
          appointment to speak again. You can reach me at {{UserEmailAddress}}
          or directly by phone at {{UserPhone}}.
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="columnD-link"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            color: #093c61;
            font-size: 15px;
            line-height: 19px;
          "
        >
          Click
          <a
            href="http://products.sanofi.us/Kevzara/Kevzara.pdf"
            target="_blank"
            style="
              margin: 0;
              border: 0;
              padding: 0;
              color: inherit;
              text-decoration: none;
            "
            ><strong style="margin: 0; border: 0; padding: 0"
              ><u style="margin: 0; border: 0; padding: 0"> here</u></strong
            >
            for full Prescribing Information, including
            <strong style="margin: 0; border: 0; padding: 0"
              >Boxed WARNING.</strong
            >
          </a>
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p
          class="columnD-link"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            color: #093c61;
            font-size: 15px;
            line-height: 19px;
          "
        >
          KEVZARA is available by prescription only.
        </p>
      </div>
      <div
        class="columnE"
        style="
          margin: 0;
          border: 0;
          padding: 4% 3%;
          color: #58595b;
          font-size: 15px;
        "
      >
        <div
          class="columnE-heading"
          style="margin: 0; border: 0; padding: 0; margin-bottom: 2%"
        >
          <p style="margin: 0; border: 0; padding: 0">
            [Regards,] <br style="margin: 0; border: 0; padding: 0" />
            [First Name, Last Name]
          </p>
        </div>
        <div class="reference-columnD" style="margin: 0; border: 0; padding: 0">
          <p style="margin: 0; border: 0; padding: 0">
            <span
              style="
                margin: 0;
                border: 0;
                padding: 0;
                font-weight: 700;
                color: #58595b;
              "
              >References: 1.</span
            >
            Genovese MC, Fleischmann R, Kivitz A J, et al. Sarilumab plus
            methotrexate in patients with active rheumatoid arthritis and
            inadequate response to methotrexate: results of a phase III study.
            Arthritis Rheumatol. 2015;67(6): 1424-1437.
            <span
              style="
                margin: 0;
                border: 0;
                padding: 0;
                font-weight: 700;
                color: #58595b;
              "
              >2.</span
            >
            KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron
            Pharmaceuticals, Inc.
            <span
              style="
                margin: 0;
                border: 0;
                padding: 0;
                font-weight: 700;
                color: #58595b;
              "
              >3.</span
            >
            Data on file, Sanofi/Regeneron. Integrated summary. October 25,
            2019.
            <span
              style="
                margin: 0;
                border: 0;
                padding: 0;
                font-weight: 700;
                color: #58595b;
              "
              >4.</span
            >
            Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and
            nonbiologic disease-modifying antirheumatic drugs in patients with
            active rheumatoid arthritis and inadequate response or intolerance
            to tumor necrosis factor inhibitors. Arthritis Rheumatol.
            2017;69(2):277-290.
            <span
              style="
                margin: 0;
                border: 0;
                padding: 0;
                font-weight: 700;
                color: #58595b;
              "
              >5.</span
            >
            Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of
            sarilumab monotherapy versus adalimumab monotherapy for the
            treatment of patients with active rheumatoid arthritis (MONARCH): a
            randomised, double-blind, parallel-group phase III trial. Ann Rheum
            Dis. 2017;76(5):840-847.
            <br style="margin: 0; border: 0; padding: 0" />
            <span
              style="
                margin: 0;
                border: 0;
                padding: 0;
                font-weight: 700;
                color: #58595b;
              "
              >6.</span
            >Humira [package insert]. North Chicago, IL: AbbVie Inc; 2019.
          </p>
        </div>
        <hr style="margin: 4% 0px; border: 1px solid #093c61; padding: 0" />
        <footer
          class="footer-section"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            line-height: 19px;
            color: #58595b;
            font-size: 12px;
          "
        ></footer>
        <p style="margin: 0; border: 0; padding: 0">
          KEVZARA is a registered trademark of Sanofi Biotechnology.
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          For Colorado Prescribers - Click
          <u style="margin: 0; border: 0; padding: 0"
            ><a
              href="https://www.sanofi.us/en/products-and-resources/colorado-disclosure"
              target="_blank"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: inherit;
                text-decoration: none;
              "
              >Here for Pricing Information.
            </a></u
          >
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <img
          src="https://res.cloudinary.com/lenilunderman/image/upload/v1621297780/axon/SanofiGenzyme_Regeneron_Horiz_4C_2x_i58aik.jpg"
          alt="Sanofi Genzyme logo and Regeneron logo"
          style="
            margin: 0;
            border: 0;
            padding: 0;
            max-width: 100%;
            object-position: center;
            object-fit: fill;
          "
        />
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          Sanofi US<br style="margin: 0; border: 0; padding: 0" />
          55 Corporate Drive <br style="margin: 0; border: 0; padding: 0" />
          Bridgewater, New Jersey 08807
          <br style="margin: 0; border: 0; padding: 0" />
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          The above promotional material is provided to you by your Sanofi sales
          professional. To opt out of receiving future promotion material
          messages from me or from other Sanofi sales professionals, click
          <u style="margin: 0; border: 0; padding: 0">
            <a
              href="https://unsubscribe.sanofi-aventis.us/"
              target="_blank"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: inherit;
                text-decoration: none;
              "
              >unsubscribe
            </a>
          </u>
          to opt out.
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          © 2020 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
          05/20
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          <u style="margin: 0; border: 0; padding: 0">
            <a
              href="https://www.sanofi.us/en/legal-notice/"
              target="_blank"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: inherit;
                text-decoration: none;
              "
            >
              Legal Disclaimer Information
            </a>
          </u>
          and
          <u style="margin: 0; border: 0; padding: 0">
            <a
              href="https://www.sanofi.us/en/legal-notice/#Privacypolicy"
              target="_blank"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: inherit;
                text-decoration: none;
              "
            >
              Privacy Policy.
            </a>
          </u>
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">
          Questions or comments? Click
          <u style="margin: 0; border: 0; padding: 0"
            ><a
              href="https://contactus.sanofi-aventis.us/"
              target="_blank"
              style="
                margin: 0;
                border: 0;
                padding: 0;
                color: inherit;
                text-decoration: none;
              "
            >
              here
            </a>
          </u>
          to contact us. This message is intended for use by US
          <br style="margin: 0; border: 0; padding: 0" />
          residents only.
        </p>
        <br style="margin: 0; border: 0; padding: 0" />
        <p style="margin: 0; border: 0; padding: 0">MAT-US-2006705</p>
      </div>
      <!-- end of content grid column d-->
    </div>
    <!--end container wrapper-->
  </body>
</html>
